Abacavir lamivudine: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''Abacavir/lamivudine''' ([[International Nonproprietary Name|INNs]]) is a [[combination drug]] for the treatment of [[HIV infection]]. It is marketed as '''Kivexa''' in most countries except for the United States, where it is branded as '''Epzicom'''.<ref>[http://www.viivhealthcare.com/en/products/epzicom-kivexa.aspx ViiV Healthcare: Kivexa]</ref> It is a [[fixed dose combination (antiretroviral)|fixed dose combination]] of [[lamivudine]] (3TC, Epivir) and [[abacavir]] (ABC, Ziagen). | |||
Lamivudine and abacavir are both [[nucleoside reverse transcriptase inhibitor]]s (NRTI). | |||
It was approved by the FDA on August 2, 2004. It is marketed by [[ViiV Healthcare]]. | |||
==Category== | ==Category== | ||
Revision as of 01:56, 10 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom.[1] It is a fixed dose combination of lamivudine (3TC, Epivir) and abacavir (ABC, Ziagen).
Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.
Category
Antiretroviral
US Brand Names
EPZICOM®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages